Prior to RSNA, we’ve been steadily
growing the user base, with Women’s &
Breast Imaging (Perth), Breast Imaging
Specialists (Los Gatos, California) and
Stanford University all signing up for
VolparaEnterprise and multiple trials
starting or moving towards completion.
RSNA has certainly let us deepen and
strengthen our sales pipeline which,
even before the meeting, was standing
at some 170 active accounts, about
30% of which had pricing proposals.
Those proposals are now predominantly
SaaS rather than the capital sales
model we previously employed.
Elizabeth Wende Breast Care in
New York has released the first
peer-reviewed article that relates
any automated volumetric density to
the risk of missing cancer. Volpara
density showed an almost perfect
linear relationship with increased
risk of missing cancer—one that
was more precise than exhibited
by visual assessment of density.
VHT Price at posting:
66.5¢ Sentiment: Buy Disclosure: Held
